MARKET

CRIS

CRIS

Curis
NASDAQ
10.14
+0.37
+3.74%
Opening 15:58 02/29 EST
OPEN
9.89
PREV CLOSE
9.77
HIGH
10.55
LOW
9.70
VOLUME
51.27K
TURNOVER
0
52 WEEK HIGH
20.00
52 WEEK LOW
3.800
MARKET CAP
59.74M
P/E (TTM)
-1.1315
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CRIS last week (0219-0223)?
Weekly Report · 3d ago
Weekly Report: what happened at CRIS last week (0212-0216)?
Weekly Report · 02/19 12:39
Weekly Report: what happened at CRIS last week (0205-0209)?
Weekly Report · 02/12 12:23
Curis Inc. Is Worried About This – Should You Be Worried Too?
TipRanks · 02/10 06:00
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
Telsey Advisory Group raised the price target for Ralph Lauren Corporation from $165 to $195. HSBC cut Bunge Global SA's price target from $122 to $105. Inotiv shares jumped 16.8% to close at $4.30 on Thursday. Wells Fargo cut Everest Group, Ltd. Price target.
Benzinga · 02/09 13:11
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Curis (CRIS)
TipRanks · 02/09 13:10
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
TipRanks · 02/09 11:20
HC Wainwright & Co. Maintains Buy on Curis, Lowers Price Target to $26
Benzinga · 02/09 11:07
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.